Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Indonesia: Trade surplus faces gradual narrowing – UOB

Indonesia: Trade surplus faces gradual narrowing – UOB

FXStreetFXStreet2026/11/03 19:24

UOB’s Enrico Tanuwidjaja highlights that Indonesia’s trade surplus stayed sizeable at USD 3.36bn in September, with exports up 11.9% year-on-year and imports rising 18.4%. He notes resilient manufacturing and commodity exports, but faster import growth tied to domestic demand and investment. The report argues this pattern points toward a wider current account deficit and a more volatile external backdrop over the medium term.

Trade buffers seen moderating ahead

"While the recent trade surpluses are encouraging, they do not signal a return to the exceptionally large and persistent surpluses seen during 2021–2025."

"However, the simultaneous acceleration in imports reflects strengthening domestic demand and points to a gradual moderation in external surpluses going forward."

"While recent trade outcomes point to a more balanced external position, the underlying trend continues to suggest a gradual narrowing of Indonesia's external buffers as domestic demand improves and investment-related imports rise."

"Consequently, Indonesia's current account balance is likely to remain in deficit over the coming quarters."

"The trend remains consistent with an expectation of a wider current account deficit and a more volatile external environment over the medium term."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12